Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.

Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J.

Am J Psychiatry. 1990 Sep;147(9):1209-15.

PMID:
2143637
2.

Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.

Flament MF, Bisserbe JC.

J Clin Psychiatry. 1997;58 Suppl 12:18-22. Review.

3.

Pharmacotherapy of obsessive compulsive disorder.

Goodman WK, McDougle CJ, Price LH.

J Clin Psychiatry. 1992 Apr;53 Suppl:29-37. Review.

PMID:
1532962
4.

Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder.

Fineberg NA, Bullock T, Montgomery DB, Montgomery SA.

Int Clin Psychopharmacol. 1992 Jun;7 Suppl 1:43-7. Review. No abstract available.

PMID:
1517558
5.

Serotonergic antidepressants and their efficacy in obsessive compulsive disorder.

Dominguez RA.

J Clin Psychiatry. 1992 Oct;53 Suppl:56-9. Review.

PMID:
1429485
6.

Obsessive-compulsive disorder: a new perspective in diagnosis and treatment.

Lydiard RB.

Int Clin Psychopharmacol. 1994 Jun;9 Suppl 3:33-7. Review.

PMID:
7963449
7.

Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies.

Chouinard G.

Int Clin Psychopharmacol. 1992 Oct;7 Suppl 2:37-41. Review.

PMID:
1484177
8.

New pharmacologic approaches to obsessive compulsive disorder.

Insel TR.

J Clin Psychiatry. 1990 Oct;51 Suppl:47-51; discussion 56-8. Review.

PMID:
2120204
9.

The pharmacotherapy of obsessive-compulsive disorder.

McDougle CJ, Goodman WK, Price LH.

Pharmacopsychiatry. 1993 May;26 Suppl 1:24-9. Review.

PMID:
8378419
10.

A review of pharmacologic treatments for obsessive-compulsive disorder.

Kaplan A, Hollander E.

Psychiatr Serv. 2003 Aug;54(8):1111-8. Review.

PMID:
12883138
11.

Serotonergic probes in obsessive compulsive disorder.

Zohar J, Kindler S.

Int Clin Psychopharmacol. 1992 Jun;7 Suppl 1:39-40. Review. No abstract available.

PMID:
1517556
12.

Serotonin and treatment in obsessive-compulsive disorder.

March JS, Gutzman LD, Jefferson JW, Greist JH.

Psychiatr Dev. 1989 Spring;7(1):1-18. Review.

PMID:
2508084
13.

Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine.

Schatzberg AF, Dessain E, O'Neil P, Katz DL, Cole JO.

J Clin Psychopharmacol. 1987 Dec;7(6 Suppl):44S-49S. Review.

PMID:
3123528
14.

Pharmacologic therapy of obsessive compulsive disorder.

DeVeaugh-Geiss J.

Adv Pharmacol. 1994;30:35-52. Review.

PMID:
7833296
15.

On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?

Todorov C, Freeston MH, Borgeat F.

Can J Psychiatry. 2000 Apr;45(3):257-62. Review.

PMID:
10779882
16.

Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.

Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ.

Int Clin Psychopharmacol. 2007 Nov;22(6):313-22. Review.

PMID:
17917549
17.

A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Carpenter LL, McDougle CJ, Epperson CN, Price LH.

Drug Saf. 1996 Aug;15(2):116-34. Review.

PMID:
8884163
18.

A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.

Pigott TA, Seay SM.

J Clin Psychiatry. 1999 Feb;60(2):101-6. Review.

PMID:
10084636
19.

Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.

Dell'Osso B, Allen A, Hollander E.

Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. Review.

PMID:
16316311
20.

An integrated approach to treatment of obsessive compulsive disorder.

Greist JH.

J Clin Psychiatry. 1992 Apr;53 Suppl:38-41. Review.

PMID:
1532963

Supplemental Content

Support Center